Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vertex Pharmaceuticals (NASDAQ: VRTX) for $85/share.
Crinetics and Vertex have entered into a definitive agreement under which Vertex will acquire Crinetics for $85 per share in cash, representing a total equity value of approximately $10 billion.
Crinetics Pharmaceuticals shares jumped 99.1% to $83.67 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers
Losers
M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition
Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the company announced it will be…
Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker…
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder,…
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid…
Quanterix shares surged 5.28% in pre-market trading on Wednesday to $3.39, reversing the prior day’s losses.
Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to…
